|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Three Months Ended |
|
|
|
March 31, 2026 |
|
|
March 31, 2025 |
|
|
|
Income |
|
|
Shares (a) |
|
|
Per Share |
|
|
Income |
|
|
Shares (a) |
|
|
Per Share |
|
|
|
(Numerator) |
|
|
(Denominator) |
|
|
Amount |
|
|
(Numerator) |
|
|
(Denominator) |
|
|
Amount |
|
Net income |
|
$ |
85,043 |
|
|
|
|
|
|
|
|
$ |
74,230 |
|
|
|
|
|
|
|
Less: Net income attributable to
noncontrolling interests |
|
|
(11,636 |
) |
|
|
|
|
|
|
|
|
(4,546 |
) |
|
|
|
|
|
|
Net income after noncontrolling
interests |
|
|
73,407 |
|
|
|
|
|
|
|
|
|
69,684 |
|
|
|
|
|
|
|
Less: Income attributable to
participating securities |
|
|
(3,255 |
) |
|
|
|
|
|
|
|
|
(3,103 |
) |
|
|
|
|
|
|
Basic Earnings Per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income attributable to common
stockholders |
|
|
70,152 |
|
|
|
12,490 |
|
|
$ |
5.62 |
|
|
|
66,581 |
|
|
|
10,286 |
|
|
$ |
6.47 |
|
Effect of Dilutive Securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options |
|
|
— |
|
|
|
398 |
|
|
|
|
|
|
— |
|
|
|
350 |
|
|
|
|
Convertible senior notes |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
1,873 |
|
|
|
2,142 |
|
|
|
|
Warrants |
|
|
— |
|
|
|
8 |
|
|
|
|
|
|
— |
|
|
|
7 |
|
|
|
|
Net impact from reallocation of
undistributed earnings to
participating securities |
|
|
78 |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
Diluted Earnings Per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income attributable to common
stockholders |
|
$ |
70,230 |
|
|
|
12,896 |
|
|
$ |
5.45 |
|
|
$ |
68,454 |
|
|
|
12,785 |
|
|
$ |
5.35 |
|
For the periods presented, all potentially dilutive securities for Exzeo were excluded from Exzeo's diluted earnings per share computation because their (i) effect would be anti-dilutive, (ii) exercise prices were out-of-the-money, or (iii) contingent exercise conditions were unsatisfied.
|